Impact of COVID-19 on metabolic parameters in patients with type 2 diabetes mellitus.

ingentiumby ingentium

In Clinical Literature.

Publication date: Feb 03, 2025

The Coronavirus Disease 2019 (COVID-19) pandemic has disproportionately affected individuals with Type 2 Diabetes Mellitus (T2DM), making them more susceptible to viral infections. Additionally, COVID-19 and the associated lockdown restrictions have influenced metabolic regulatory mechanisms in this population. This study aims to evaluate the impact of COVID-19 infection and lockdown measures on physiological parameters in individuals with T2DM. This retrospective cohort study included 118 individuals with a prior diagnosis of T2DM. Medical records were reviewed for laboratory tests conducted within three months before the onset of the COVID-19 pandemic in Iran. Fifty-nine patients with confirmed COVID-19 infection during the first three months of the pandemic underwent follow-up laboratory tests six months post-diagnosis. An age- and gender-matched group of 59 noninfected individuals underwent follow-up tests six months after the pandemic’s onset. Clinical and laboratory parameters were analyzed and compared within each group. In the COVID-19 positive group, significant reductions were observed in triglycerides (TG) (P = 0. 001), total cholesterol (TC) (P = 0. 028), body mass index (BMI) (P = 0. 034), atherogenic index of plasma (AIP) (P = 0. 027), triglyceride-glucose (TyG) index (P = 0. 001), and triglyceride-glucose-BMI (TyG-BMI) index (P 

Open Access PDF

Concepts Keywords
Coronavirus Cohort study
Diabetes COVID-19
Iran Metabolic profile
Pandemic Type 2 diabetes

Semantics

Type Source Name
disease MESH COVID-19
disease MESH type 2 diabetes mellitus
disease MESH viral infections
disease MESH infection
drug DRUGBANK Cholesterol
drug DRUGBANK Dextrose unspecified form
disease MESH Long Covid
pathway REACTOME Reproduction
drug DRUGBANK Coenzyme M
disease MESH Non Communicable Diseases
disease MESH Diabetes Mellitus
disease IDO history
disease MESH insulin resistance
pathway KEGG Insulin resistance
disease MESH hyperglycemia
pathway REACTOME Metabolism
drug DRUGBANK ATP
disease IDO production
disease IDO replication
disease IDO host
disease IDO blood
disease IDO susceptibility
pathway KEGG Insulin secretion
disease IDO acute infection
disease MESH lifestyle
drug DRUGBANK Methionine
drug DRUGBANK Atorvastatin
disease MESH neoplasia
disease MESH reinfection
drug DRUGBANK Urea
drug DRUGBANK Nitrogen
drug DRUGBANK Creatinine
drug DRUGBANK Alpha-1-proteinase inhibitor
disease MESH dyslipidemia
disease MESH inflammation
disease MESH taste disorders
disease MESH malnutrition
disease MESH weight loss
disease MESH obesity
disease MESH chronic condition
drug DRUGBANK Isoxaflutole
disease MESH emergency
disease MESH emotional stress
disease MESH physical inactivity
drug DRUGBANK Water
disease MESH albuminuria
disease MESH death
pathway REACTOME Glycolysis
drug DRUGBANK Honey
disease MESH atherosclerosis
disease MESH diabetes complications
disease MESH visceral obesity
drug DRUGBANK Tolbutamide
disease MESH cardiovascular disease
disease MESH cardiovascular risk
disease MESH Hypertension
disease MESH acute kidney injury
drug DRUGBANK Creatine
disease MESH critically ill

Original Article

(Visited 1 times, 1 visits today)